JMDC's Pharma-Data Rebound Pushes First-Quarter Profit Up 17%, Prompts Rare Half-Year Forecast
JMDC's April-June profit rose 17% on faster-than-planned pharma demand for its health data, and the company broke its own rule against forecasting the first half, even as it keeps its full-year target unchanged.